NCT00546936 - Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

April 30, 2010

Conditions

Presumed Ocular Histoplasmosis (POHS)

Interventions

DRUG

ranibizumab

0.5mg ranibizumab

DRUG

verteporfin

Photodynamic therapy with verteporfin every 3 months for 1 year

Trial Locations (2)

RECRUITING

Macula-Retina-Vitreous Service, Midwest Eye Institute, Indianapolis

RECRUITING

Barnes Retina Institute, St Louis